Differentiation between carcinoid and sarcoid with F-18 FDG PET and In-111 pentetreotide

Clinical Nuclear Medicine

Volumn 31, Issue 4, 2006, Pages 197-200

  Avram, Anca M ^a   Mackie, Gavin C ^a   Schneider, Bryan J ^b   Kalemkerian, Gregory P ^b   Shulkin, Barry L ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Carcinoid; FDG PET; Neuroendocrine tumor; Pentetreotide; Sarcoidosis; Somatostatin receptors

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; DIAGNOSTIC AGENT; DRUG DERIVATIVE; INDIUM; PENTETREOTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN;

ADULT; ARTICLE; BRONCHUS TUMOR; CARCINOID; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; HUMAN; LUNG HILUS; LYMPH NODE; LYMPHADENOPATHY; MALE; MEDIASTINUM; NEUROENDOCRINE TUMOR; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; SARCOIDOSIS; SCINTISCANNING; TUMOR DIAGNOSIS; WEIGHT REDUCTION; COMPUTER ASSISTED EMISSION TOMOGRAPHY;

ADULT; BRONCHIAL NEOPLASMS; CARCINOID TUMOR; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; INDIUM RADIOISOTOPES; RADIOPHARMACEUTICALS; SARCOIDOSIS; SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 33748096970     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000204200.66112.a9     Document Type: Article

References (21)

1. de Hemricourt E, De Boeck K, Hilte F, et al. Sarcoidosis and sarcoid-like reaction following Hodgkin's disease. Report of two cases. Mol Imaging Biol. 2003;5:15-19.
2. Brinker H. Sarcoid reactions in malignant tumors. Cancer Treat Rev. 1986;13:147-156.
3. Miyazaki Y, Miyake S, Taki R, Ohkouchi Y, Matsubara O, Yoshizawa Y. Intern Med. 1998;37:304-306.
4. Weltfriend S, Harth Y, Katz I. Subcutaneous sarcoidosis in a patient with malignant carcinoid tumor of the colon. J Am Acad Dermatol. 1989;20:507-508.
5. Grazia M, Ansaloni L, Bini A, et al. A pitfall with the use of 111-In pentetreotide scintigraphy in the resected bronchopulmonary carcinoids follow-up: a case report. Acta Chir Hung. 1999;38:35-37.
6. Levy NT, Rubin J, DeRemee RA, Aughenbaugh GL, Unni KK, Kahn MJ. Carcinoid tumors and sarcoidosis - does a link exist? Mayo Clin Proc. 1997;72:112-116.
7. Garcia CA, Rosenberg RJ, Spencer RP. FDG-positron emission tomographic imaging in carcinoma of the breast: interference by massive sarcoidosis. Clin Nucl Med. 2003;28:218-219.
8. Ludwig V, Fordice S, Lamar R, Martin WH, Delbeke D. Unsuspected skeletal sarcoidosis mimicking metastatic disease on FDG positron emission tomography and bone scintigraphy. Clin Nucl Med. 2003;28:176-179.
9. Karapetis CS, Strickland AH, Yip D, van der Walt JD, Harper PG. PET and PLAP in suspected testicular cancer relapse: beware sarcoidosis. Ann Oncol. 2001;12:1485-1488.
10. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994;35:1647-1649.
11. Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)FFDG PET. J Nucl Med. 2003;44:1030-1036.
12. Lebtahi R, Crestani R, Belmatoug N, et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med. 2001;42:21-26.
13. Kwekkeboom DJ, Krenning EP, Kho GS, Breeman WA, Van Hagen PM. Somatostatin receptor imaging in patients with sarcoidosis. Eur J Nucl Med. 1998;25:1284-1292.
14. Granberg D, Sundin A, Janson ET, Oberg K, Skogseid B, Westlin JE. Octreoscan in patients with bronchial carcinoid tumors. Clin Endocrinol (Oxf). 2003;59:793-799.
15. Fanti S, Farsad M, Battista G, et al. Somatostatin receptor scintigraphy for bronchial carcinoid follow-up. Clin Nucl Med. 2003;28:548-552.
16. Erasmus JJ, McAdams HP, Patz EF Jr, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol. 1998;170:1369-1373.
17. Marom EM, Sarvis S, Herndon JE 2nd, Patz EF Jr. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology. 2002;223:453-459.
18. Jadvar H, Segall GM. False-negative fluorine-18-FDG PET in metastatic carcinoid. J Nucl Med. 1997;38:1382-1383.
19. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998;25:79-83.
20. Le Rest C, Bomanji JB, Costa DC, Townsend CE, Visvikis D, Ell PJ. Functional imaging of malignant paragangliomas and carcinoid tumours. Eur J Nucl Med. 2001;28:478-482.
21. Belhocine T, Foidart J, Rigo P, et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun. 2002;23:727-734.